

Contents

Contributors, xxvii

Editor's Preface, xxxv

Section I: An overview of mesenchymal stem cells and mesenchymal stromal cells

- 1** The mesenchymal stem cell, the mesenchymal stromal cell, and the mesenchymal stromal cell exosome, 3
Kerry Atkinson

- 1.1 Nomenclature, 3
- 1.2 The mesenchymal stem cell, 3
- 1.3 The mesenchymal stromal cell, 4
- 1.4 The mesenchymal stromal cell exosome and extracellular vesicles, 6
- References, 7

- 2** The nomenclature of mesenchymal stem cells and mesenchymal stromal cells, 8
Armand Keating
- 2.1 Introduction, 8
 - 2.2 Historical perspective, 8
 - 2.3 The need for common terminology and definition: the International Society for Cellular Therapy white papers of the mid-2000s, 9
 - 2.4 Updating terminology, 9
 - References, 10

Section II: The isolation and ex vivo expansion of mesenchymal stromal cells

- 3** The isolation and expansion of mesenchymal stromal cells from bone marrow, 13
Celena F. Heazlewood
- 3.1 Introduction, 13
 - 3.2 Stem cells, 14
 - 3.3 Isolation and characterization of bone marrow mesenchymal stromal cells, 14
 - 3.3.1 Cell surface markers, 15
 - 3.3.2 Chemokine receptor display, 15
 - 3.3.3 Mesodermal differentiation capability, 17

- 3.4 The immunomodulatory properties of mesenchymal stromal cells, 17
- 3.5 The transcriptome of mesenchymal stromal cells, 18
- References, 20

- 4** The biology and clinical applications of mesenchymal stromal cells derived from human gestational tissues, 24
Celena F. Heazlewood
- 4.1 Introduction, 24
 - 4.2 Isolation of placental mesenchymal stromal cells, 25
 - 4.3 Characteristics of fetally derived mesenchymal stromal cells isolated from gestational tissues, 26
 - 4.3.1 Amniotic-membrane-derived mesenchymal stromal cells, 26
 - 4.3.2 Chorionic-membrane-derived mesenchymal stromal cells, 26
 - 4.4 Characteristics of maternally derived mesenchymal stromal cells isolated from gestational tissue (the decidua), 27
 - 4.5 Comparison of mesenchymal stromal cells from fetal and maternal tissues isolated from gestational tissues, 27
 - 4.6 Comparison of gene expression profiles between human term-placenta-derived mesenchymal stromal cells, human adult bone-marrow-derived mesenchymal stromal cells, and human umbilical-cord-derived unrestricted somatic stem cells, 28
 - 4.7 Preclinical mesenchymal stromal cell studies, 28
 - 4.8 Clinical applications of placental mesenchymal stromal cells, 29
 - 4.9 Manufacturing clinical-grade placenta-derived mesenchymal stromal cells, 29
 - 4.9.1 Phase 1 clinical trials using unrelated major-histocompatibility-unmatched placenta-derived mesenchymal stromal cells, 30
 - 4.10 Conclusions, 30
 - References, 30

- 5** Human placenta-derived mesenchymal stem/stromal cells: fetal and maternal origins and critical parameters for ex vivo expansion, 32
Rebecca A. Pelekanos and Varda S. Sardesai
- 5.1 Introduction, 32

5.2 Mesenchymal stem/stromal cells: a consensus definition?, 32
5.3 Prenatal and perinatal tissue sources of mesenchymal stem/stromal cells, 33
5.4 Fetal tissue-derived mesenchymal stem/stromal cells, 33
5.5 Placental and adnexal stem and progenitor cells, 33
5.6 Comparison of mesenchymal stem/stromal cells from different gestational sources, 33
5.7 Consensus classification of human placental mesenchymal stem/stromal cells, 34
5.8 Differentially isolating fetal or maternal mesenchymal stem/stromal cells from term placental villi, 34
5.9 Confounding factors for the isolation of fetal placental mesenchymal stem/stromal cells from chorionic villi, 34
5.10 Assumptions from the literature: lack of data, specific assays, and specific methodological detail, 35
5.11 Methods for determining fetal and maternal mesenchymal stem/stromal cells in a cultured cell population, 35
5.12 A novel method to isolate fetal and maternal placental mesenchymal stem/stromal cells, 36
5.13 Understanding the maternal origin of the placental mesenchymal stem/stromal cells: the septa, 36
5.14 Conclusions and future directions, 36
Acknowledgments, 37
References, 37

Section III: The cellular and molecular biology of mesenchymal stromal cells

6 Epigenetic regulation of mesenchymal stem/stromal cell growth and multipotentiality, 41
<i>Sarah Elizabeth Hemming, Dimitrios Cakouros, and Stan Gronthos</i>
6.1 Introduction, 41
6.2 Mesenchymal stromal/stem cells, 42
6.3 Epigenetics, 42
6.4 DNA methylation and histone modifications in mesenchymal stem/stromal cells, 45
6.5 Epigenetic regulation of osteogenic differentiation, 45
6.6 Epigenetic regulation of adipogenic differentiation, 47
6.7 Epigenetic regulation of myogenic differentiation, 48
6.8 Epigenetic regulation of chondrogenic differentiation, 48
6.9 Epigenetic regulation of mesenchymal stem/stromal cell lifespan and senescence, 52
6.10 Regulation of epigenetic modifications in mesenchymal stem/stromal cells for clinical use, 52
6.11 Conclusions, 52
References, 53

7 Biological changes in human mesenchymal stromal cells during monolayer culture, 58
<i>Marietta Herrmann and Jennifer J. Bara</i>
7.1 Introduction, 58
7.2 Mesenchymal stromal cell isolation from bone marrow, 59
7.3 Mesenchymal stromal cell isolation from adipose tissue, 60
7.4 Biological characteristics, 60
7.4.1 Morphology and colony formation, 60
7.4.2 Growth kinetics, 61
7.4.3 <i>In vitro</i> multipotency, 62
7.4.4 Gene expression, 62
7.4.5 Cell surface marker profile, 63
7.4.6 Secretory profile, 66
7.5 Influences on tissue culture parameters, 66
7.5.1 Seeding density, 66
7.5.2 Culture medium and supplementation, 67
7.5.3 Growth factors, 67
7.5.4 Xeno-free media, 67
7.5.5 Platelet-derived supplements, 67
7.5.6 Serum-free media, 68
7.5.7 Hypoxia, 68
7.6 Implications for basic and clinical research, 68
7.6.1 Trial disparity, 68
7.6.2 Alternative culture systems, 69
7.7 Conclusions and future directions, 70
References, 70
8 The effect of three-dimensional aggregates on the biology of mesenchymal stromal cells, 75
<i>Yijun Liu, Ang-Chen Tsai, Xuegang Yuan, and Teng Ma</i>
8.1 Three-dimensional multicellular aggregates, 75
8.2 Three-dimensional aggregates of mesenchymal stromal cells, 76
8.3 Mechanism of mesenchymal stromal cells self-assembly into three-dimensional aggregates, 77
8.3.1 Cell-cell contact, 77
8.3.2 Extracellular matrix and the cytoskeleton, 77
8.3.3 Mesenchymal stromal cells heterospheroids, 78
8.4 Mechanisms of aggregate-mediated mesenchymal stromal cell functional enhancement, 78
8.4.1 Role of cell adhesion molecules in the fate decision of mesenchymal stromal cell three-dimensional aggregates, 79
8.4.2 Effects of extracellular matrix, cytoskeleton, and morphology on mesenchymal stromal cell lineage commitment in three-dimensional aggregates, 80
8.4.3 Role of molecular milieu and hypoxia-inducible factor activation, 80
8.4.4 Metabolism changes in three-dimensional aggregates of mesenchymal stromal cells, 81

- 8.4.5 Enhanced anti-inflammatory properties of three-dimensional aggregates of mesenchymal stromal cells, 81
- 8.5 Bioreactor systems for three-dimensional aggregate production, 81
 - 8.5.1 Scale-up and dynamics of culture, 81
 - 8.5.2 Spinner flasks, 82
 - 8.5.3 Rotary wall vessel, 82
 - 8.5.4 Rotary orbital system, 83
 - 8.5.5 Comparison of spinner flask and rotary wall vessel, 83
 - 8.5.6 Other systems, 84
- 8.6 Transplantation of three-dimensional mesenchymal stromal cell aggregates in preclinical animal models of disease, 84
 - 8.6.1 Enhanced secretory properties of mesenchymal stromal cells aggregates, 84
 - 8.6.2 Immunomodulation by mesenchymal stromal cell aggregates, 84
 - 8.6.3 Enhanced multilineage differentiation of three-dimensional mesenchymal stromal cells aggregates, 84
 - 8.6.4 Recapitulation of mesenchymal condensation and osteochondral differentiation in bone and cartilage regeneration, 86
- References, 87
- 9** Cell-cell signaling pathways that regulate mesenchymal stromal cell differentiation, 91
Leah Etheridge, Rebecca A. Mason, Fatima Saleh, and Paul Genever
 - 9.1 Introduction, 91
 - 9.2 Mesenchymal stromal cell signaling is dependent on its type, 91
 - 9.3 Identity of bone-marrow-derived mesenchymal stromal cells, 92
 - 9.4 Mesenchymal stromal cell signaling in the stem cell niche, 93
 - 9.5 Regulation of mesenchymal stromal cell differentiation by the TGF- β /BMP signaling pathway, 95
 - 9.6 Regulation of mesenchymal stromal cell differentiation by the Wnt signaling pathway, 97
 - 9.7 Conclusions, 99
 - References, 99
- 10** Regulation of mitochondrial transport in mesenchymal stromal cells, 104
Shravani Mukherjee, Naveen K. Bhatraju, Tanveer Ahmad, and Anurag Agrawal
 - 10.1 Introduction, 104
 - 10.2 Intercellular organelle transport, 105
 - 10.2.1 Intercellular communication, 105
 - 10.2.2 Mitochondrial biology, 105
 - 10.2.3 Intercellular mitochondrial transport/mitochondrial donation, 105
 - 10.3 Mesenchymal stromal cells as potential mitochondrial donors, 107
 - 10.3.1 Mechanism of intercellular mitochondrial transport regulation, 108
 - 10.4 Strategies to improve mitochondrial delivery to target cells, 110
 - 10.5 The road ahead, 111
 - References, 111
- 11** The regulation of adipogenesis from adipose-derived stem/stromal cells, 114
Lin Chen and Lei Liu
 - 11.1 Introduction, 114
 - 11.2 Adipose-derived stem/stromal cells, 115
 - 11.2.1 Preparation and molecular characterization of adipose-derived stem/stromal cells, 115
 - 11.2.2 Differentiation capacity of adipose-derived stem/stromal cells, 116
 - 11.3 Process of adipogenic differentiation from adipose-derived stem/stromal cells, 116
 - 11.3.1 Adipocyte development program, 116
 - 11.3.2 Signaling pathways associated with adipogenic differentiation, 117
 - 11.4 Regulation of adipogenic differentiation from adipose-derived stem/stromal cells, 118
 - 11.4.1 Transcriptional regulation, 118
 - 11.4.2 Epigenetic regulation, 119
 - 11.4.3 Post-transcriptional regulation, 121
 - 11.5 The future, 125
 - References, 125
- 12** Modulation of osteogenic differentiation in mesenchymal stromal cells, 131
Sean Gaynard, Jessica Hayes, and Mary Murphy
 - 12.1 Introduction, 131
 - 12.2 Biology, 132
 - 12.2.1 Sources of mesenchymal stromal cells, 132
 - 12.2.2 Cellular regulation of osteogenic differentiation from mesenchymal stromal cells, 132
 - 12.2.3 Molecular regulation of osteogenic differentiation from mesenchymal stromal cells, 134
 - 12.2.4 Factors regulating homing of mesenchymal stromal cells to bone, 136
 - 12.2.5 *In vivo* detection and contribution of mesenchymal stromal cells to osteogenesis, 137
 - 12.2.6 Regulating the immune system for bone formation, 138
 - 12.3 Clinical applications of mesenchymal stromal cells in bone disorders, 138
 - 12.3.1 Bone regeneration, 138

- 12.3.2 Osteoarthritis, 139
 - 12.3.3 Osteogenesis imperfecta, 140
 - 12.4 Summary, 141
 - References, 141
- 13** The role of glycogen synthase kinase-3 inhibitors on bone remodeling, 148
K. Jane Escott and Patrick J. O'Shea
 - 13.1 Overview of glycogen synthase kinase-3, 148
 - 13.2 The response of skeletal cells to glycogen synthase kinase-3 inhibitors *in vitro*, 149
 - 13.2.1 Lithium chloride, 149
 - 13.2.2 SB-216763 and SB-415286, 151
 - 13.2.3 6-bromindirubin-3'-oxime, 152
 - 13.2.4 LY603281-31-8, 153
 - 13.2.5 CT99021/CHIR99021, 153
 - 13.2.6 AR28 (AZD2858), AR79, and AZ13282107, 154
 - 13.3 Bone anabolism through inhibition of glycogen synthase kinase-3 *in vivo*, 155
 - 13.3.1 Functional Wnt/ β -catenin responses in *Xenopus laevis* model systems, 156
 - 13.3.2 Progenitor cell involvement in bone anabolism *in vivo*, 156
 - 13.3.3 Alteration in bone resorption *in vivo*, 158
 - 13.4 Impact of glycogen synthase kinase-3 inhibition in bone disease, 159
 - 13.4.1 Osteopenia and osteoporosis, 159
 - 13.4.2 Methotrexate-induced bone loss, 160
 - 13.4.3 Fracture healing, 160
 - 13.4.4 Multiple myeloma-associated bone disease, 161
 - 13.4.5 Periodontal disease, 161
 - 13.4.6 Clinical findings with lithium, 161
 - 13.5 Summary, 162
 - References, 163
- 14** Early molecular events during *in vitro* chondrogenesis, 167
Tommy A. Karlsen, Rune B. Jakobsen, and Jan E. Brinchmann
 - 14.1 Introduction, 167
 - 14.2 Adult articular cartilage, 168
 - 14.3 Developmental chondrogenesis, 168
 - 14.4 Molecular aspects of *in vivo* chondrogenesis, 169
 - 14.5 Determinants of *in vitro* chondrogenesis, 171
 - 14.6 Tissue source of mesenchymal stromal cells, 171
 - 14.6.1 *In vitro* cell culture, 171
 - 14.7 Three-dimensional culture systems and bioscaffolds, 172
 - 14.8 Epigenetic changes during early *in vitro* chondrogenesis, 172
 - 14.8.1 An introduction to epigenetics, 172
 - 14.8.2 DNA methylation of the *COL2A1* and *COL10A1* promoters, 173
 - 14.8.3 DNA methylation of promoters in other chondrogenesis candidate genes, 173
 - 14.8.4 Genome-wide map of quantified epigenetic changes during *in vitro* chondrogenesis of bone marrow mesenchymal stromal cells, 174
 - 14.8.5 Epigenetics: conclusions, 175
 - 14.9 Role of microRNAs during early *in vitro* chondrogenesis, 176
 - 14.9.1 An introduction to microRNAs, 176
 - 14.9.2 Role of miRNA-140 in developmental chondrogenesis, 177
 - 14.9.3 miR-140 targets identified *in vivo* and *in vitro*, 178
 - 14.9.4 Defining the role of miR-140 during chondrogenic differentiation of mesenchymal stromal cells and dedifferentiation of articular chondrocytes, 178
 - 14.9.5 Impact of microRNAs other than miR-140 on chondrogenic differentiation of mesenchymal stromal cells, 179
 - 14.9.6 MicroRNAs in chondrogenesis: conclusions, 181
 - 14.10 Early changes in gene expression during *in vitro* chondrogenesis, 182
 - 14.10.1 Genes involved in collagen fibrillogenesis, 183
 - 14.10.2 Genes involved in synthesis of proteoglycans and glycosaminoglycans, 183
 - 14.10.3 Transcription factor genes, 183
 - 14.10.4 Genes encoding other important cartilage molecules, 184
 - 14.10.5 Genes encoding unwanted molecules, 184
 - 14.10.6 Effect on gene expression of changes in the differentiation cocktail, 184
 - 14.11 Conclusions, 186
 - References, 186
- 15** The role of the extracellular matrix in the differentiation of mesenchymal stromal cells, 191
Peishun Shou, Qing Chen, and Yufang Shi
 - 15.1 Summary, 191
 - 15.2 Multipotency of mesenchymal stromal cells, 191
 - 15.3 The extracellular matrix and mesenchymal stromal cell differentiation, 192
 - 15.3.1 The role of osteopontin in mesenchymal stromal cell differentiation, 193
 - 15.3.2 Geometric cues in mesenchymal stromal cell differentiation, 193
 - 15.3.3 Crosstalk between the extracellular matrix and mesenchymal stromal cells, 193
 - 15.4 Conclusions and future perspectives, 194
 - Acknowledgments, 194
 - References, 194

- 16** Effects of hypoxic culture on bone marrow multipotent mesenchymal stromal cells: from bench to bedside, 196
Shih-Chieh Hung
- 16.1 Introduction, 196
 - 16.2 Multipotent mesenchymal stromal cells, 196
 - 16.3 Criteria for defining human multipotent stromal cells, 197
 - 16.4 Problems encountered in the clinical application of multipotent mesenchymal stromal cells, 197
 - 16.5 The hypoxic niche of multipotent mesenchymal stromal cells, 197
 - 16.6 Involvement of hypoxia-inducible factor-1 α in hypoxia-mediated effects, 198
 - 16.7 Effects of hypoxic culture on glucose metabolism and oxidative stress of multipotent mesenchymal stromal cells, 198
 - 16.8 Effects of hypoxic culture on the apoptosis of multipotent mesenchymal stromal cells, 199
 - 16.9 Effects of hypoxic culture on expansion and life span of multipotent mesenchymal stromal cells, 199
 - 16.10 Effects of hypoxic culture on maintaining self-renewal and differentiation potential of multipotent mesenchymal stromal cells, 200
 - 16.11 Differentiation of multipotent mesenchymal stromal cells under hypoxic conditions, 200
 - 16.12 Effects of hypoxic culture on secretion of paracrine factors by multipotent mesenchymal stromal cells, 201
 - 16.13 Effects of hypoxic culture on engraftment of multipotent mesenchymal stromal cells, 202
 - 16.14 Effects of hypoxic culture on allogeneic transplantation of multipotent mesenchymal stromal cells, 202
 - 16.15 Conclusions, 203
 - Acknowledgments, 203
 - References, 203
- 17** The role of cyclic tensile strain on osteogenesis and angiogenesis in human mesenchymal stem/stromal cells, 208
Adisri Charoenpanich, Josephine Bodle, and Elizabeth Lobo
- 17.1 Introduction, 208
 - 17.2 Applications of tensile strain: an interpretation from physiological stimuli *in vivo* to bioreactors *in vitro*, 209
 - 17.2.1 Uniaxial tensile strain, 209
 - 17.2.2 Equi-/biaxial tensile strain, 210
 - 17.3 Mechanical sensing of mesenchymal stem/stromal cells, 211
 - 17.3.1 Integrins and the cytoskeleton, 211
 - 17.3.2 The nucleoskeleton and lamins, 212
 - 17.3.3 Primary cilia, 212
 - 17.3.4 Stretch-activated calcium channels, 213
 - 17.3.5 The glycocalyx, 213
 - 17.4 The molecular response of mesenchymal stem/stromal cells to cyclic tensile strain, 214
 - 17.4.1 Restructuring of mesenchymal stem/stromal cells and the surrounding extracellular matrix by mesenchymal stem/stromal cells in response to cyclic tensile strain, 215
 - 17.4.2 Mesenchymal stem/stromal cell secretomes that induce further responses from other cells, 216
 - 17.5 Summary, 217
 - Acknowledgments, 217
 - References, 217
- 18** The evolving concept of mesenchymal stromal cells in regenerative medicine: from cell differentiation to secretome, 222
F.G. Teixeira, A. Pires, S.C. Serra, N. Sousa, and A.J. Salgado
- 18.1 Mesenchymal stromal cells, 222
 - 18.2 The mesenchymal stromal cell secretome, 224
 - 18.2.1 Concept, 224
 - 18.2.2 Characterization techniques, 224
 - 18.3 The mesenchymal stromal cell secretome in transplantation and regenerative medicine, 225
 - 18.3.1 Graft-versus-host-disease, 225
 - 18.3.2 The central nervous system, 226
 - 18.4 The peripheral nervous system, 229
 - 18.5 Future perspectives, 230
 - References, 231
- 19** The secretome of mesenchymal stem/stromal cells undergoing chondrogenic differentiation and those undergoing osteogenic or adipogenic differentiation, 236
Beatriz Rocha, Francisco J. Blanco, and Cristina Ruiz-Romero
- 19.1 Introduction to protein secretion and the analysis of secretomes, 236
 - 19.2 Analysis of mesenchymal stem/stromal cell secretomes using proteomic approaches, 237
 - 19.2.1 Approaches to obtaining secretome samples, 237
 - 19.2.2 Experimental strategies for *in vitro* secretome analysis of mesenchymal stem/stromal cells, 237
 - 19.3 Analysis of the secretome of mesenchymal stem/stromal cells undergoing chondrogenesis, 242
 - 19.4 Characterization of chondrogenesis markers by secretome analysis, 242
 - 19.5 Characterization of osteogenesis markers by secretome analysis, 247
 - 19.6 Characterization of adipogenesis markers by secretome analysis, 247
 - 19.7 Conclusions and future perspectives, 247
 - References, 247

- 20** Mesenchymal stromal cell extracellular vesicles/exosomes, 250
Ronne Wee Yeh Yeo, Ruenn Chai Lai, and Sai Kiang Lim
 - 20.1 From cell to secretion to exosome, 250
 - 20.1.1 Mesenchymal stromal cells, 250
 - 20.1.2 Cell secretion, 251
 - 20.1.3 Mesenchymal stromal cell extracellular vesicles as the active therapeutic factor, 251
 - 20.2 Extracellular vesicles, 251
 - 20.2.1 Exosome biology and general functions, 252
 - 20.3 The therapeutic use of exosomes, 252
 - 20.3.1 Mesenchymal stromal cell exosomes, 253
 - 20.3.2 Characterization of mesenchymal stromal cell exosomes, 254
 - 20.3.3 The biochemical potential of mesenchymal stromal cell exosomes, 254
 - 20.3.4 Biochemical potency, 255
 - 20.3.5 Glycolysis, 256
 - 20.3.6 Proteasome activity, 256
 - 20.3.7 Signaling: adenosine signaling, 256
 - 20.3.8 Inhibition of complement activation, 256
 - 20.3.9 Restoring homeostasis, 256
 - 20.3.10 Bioenergetic homeostasis, 257
 - 20.3.11 Immune homeostasis, 257
 - 20.4 The clinical translation of mesenchymal stromal cell exosomes, 258
 - 20.5 Conclusions, 258
 - References, 258
- 21** Role of tunneling nanotube crosstalk with distressed cardiomyocytes in controlling the heart repair potential of mesenchymal stromal cells, 264
Anne-Marie Rodriguez and Meriem Mahrouf-Yorgov
 - 21.1 Introduction, 264
 - 21.2 Mesenchymal stromal cells as a promising tool to regenerate damaged heart tissue, 264
 - 21.2.1 Degenerative cardiac diseases: a major public health problem, 264
 - 21.2.2 Mesenchymal stromal cells: a promising tool to treat the effects of myocardial infarction, 265
 - 21.2.3 Mechanisms underlying the regenerative effects of mesenchymal stromal cells, 266
 - 21.3 Tunneling nanotubes: a universal route of intercellular communication between distant cells, 268
 - 21.3.1 Structural diversity of tunneling nanotubes, 269
 - 21.3.2 Mechanisms and factors involved in tunneling nanotube formation, 269
 - 21.3.3 The diversity of compounds transferred by tunneling nanotubes and their physiological relevance, 271
 - 21.4 Tunneling nanotubes: a novel cell-to cell communication pathway improving the cardiac regenerative properties of mesenchymal stromal cells, 273
 - 21.4.1 Evidence of tunneling-nanotube-mediated communications between stromal cells and cardiomyocytes, 273
 - 21.4.2 Tunneling nanotube cell-to-cell communication with mesenchymal stromal cells rejuvenates distressed cardiomyocytes through a progenitor-like state, 275
 - 21.4.3 Tunneling nanotube cell-to-cell communication with distressed cardiomyocytes stimulates the paracrine repair function of mesenchymal stromal cells, 277
 - 21.5 Conclusions, 279
 - References, 280
- 22** The preferential homing of mesenchymal stromal cells to sites of inflammation, 286
Catherine Sullivan
 - 22.1 Introduction, 286
 - 22.2 Molecular mechanisms of migration, 287
 - 22.2.1 Chemokines, 287
 - 22.2.2 Integrins, 289
 - 22.2.3 Toll-like receptors, 289
 - 22.2.4 Matrix metalloproteinases, 290
 - 22.2.5 Growth factors, 291
 - 22.3 The inflammatory milieu, 291
 - 22.3.1 Passive migration, 291
 - 22.3.2 Hypoxia, 291
 - 22.3.3 Cytokines, 292
 - 22.3.4 Complement, 293
 - 22.3.5 Macrophages, 294
 - 22.4 Mesenchymal stromal cell extravasation, 294
 - 22.5 *In vivo* migration, 294
 - 22.5.1 *In vivo* migration studies, 294
 - 22.5.2 Controversies surrounding *in vivo* migration, 297
 - 22.5.3 Real-time *in vivo* imaging, 301
 - 22.6 Optimizing homing, 302
 - 22.6.1 Culture conditions, 302
 - 22.6.2 Pretreatment of mesenchymal stromal cells, 303
 - 22.6.3 Cell engineering, 303
 - 22.6.4 The host environment, 304
 - 22.7 Conclusions, 305
 - References, 306
- 23** The role of chemokines in mesenchymal stromal cell homing to sites of inflammation, including infarcted myocardium, 314
Shan Wang and Yaojiong Wu
 - 23.1 Summary, 314

- 23.2 Introduction, 314
- 23.3 Homing capacity of mesenchymal stromal cells, 315
- 23.4 Homing ability of mesenchymal stromal cells and their therapeutic effects, 316
- 23.5 Mechanisms of leukocyte trafficking to sites of inflammation, 316
- 23.6 Potential ligands/receptors for mesenchymal stromal cell homing, 317
- 23.7 Chemokine involvement in mesenchymal stromal cell homing, 317
 - 23.7.1 CCR1 and CCR2 involvement in mesenchymal stromal cell homing, 317
 - 23.7.2 The CXCR4–SDF-1 axis in mesenchymal stromal cell homing, 318
 - 23.7.3 Other chemokines, 319
- 23.8 Pretreatment of mesenchymal stromal cells with cytokines and growth factors, 319
- 23.9 Summary and future prospects, 319
- Acknowledgments, 319
- References, 320
- 24 Live cell imaging and single cell tracking of mesenchymal stromal cells *in vitro*, 323**
James A. Cornwell, Maria Z. Gutierrez, Richard P. Harvey and Robert E. Nordon
 - 24.1 Introduction, 323
 - 24.2 Technical considerations, 326
 - 24.2.1 Equipment, software, and hardware requirements, 326
 - 24.2.2 Image acquisition parameters, 327
 - 24.2.3 Image processing, 327
 - 24.2.4 Data storage, 328
 - 24.3 Single cell tracking and analysis, 329
 - 24.3.1 Cell tracking platforms, 329
 - 24.3.2 Recording live cell characteristics, 331
 - 24.3.3 Vital biomarkers for mesenchymal stromal cells, 332
 - 24.3.4 Mimicking *in vivo* microenvironments *in vitro*, 335
 - 24.4 Case study: tracking differentiation of endothelial cells from cardiac-derived mesenchymal stromal cells, 337
 - 24.4.1 Background and experimental aims, 337
 - 24.4.2 Methods, 337
 - 24.4.3 Results and discussion, 340
 - 24.4.4 Conclusion and future work, 342
 - 24.5 Future perspective on live cell imaging and single cell tracking, 342
 - References, 344
- 25 The role of mesenchymal stem/stromal cells in angiogenesis, 347**
Annelies Bronckaers and Ivo Lambrechts
 - 25.1 Introduction, 347
 - 25.2 The current concept of angiogenesis, 347
 - 25.3 Proangiogenic properties of mesenchymal stem/stromal cells, 350
 - 25.3.1 The mesenchymal stem/stromal cell secretome: a kaleidoscope of angiogenic molecules, 350
 - 25.3.2 The effect of mesenchymal stem/stromal cells on the behavior of endothelial cells *in vitro*, 352
 - 25.3.3 Mesenchymal stem/stromal cells induce angiogenesis *in vivo*, 354
 - 25.4 Mesenchymal stem/stromal cells as a therapeutic tool for diseases caused by insufficient angiogenesis, 355
 - 25.4.1 Peripheral ischemic arterial disease, 355
 - 25.4.2 Stroke, 355
 - 25.4.3 Myocardial infarction, 356
 - 25.4.4 Failure of surface wound healing, 357
 - 25.4.5 The dual role of mesenchymal stem/stromal cells in cancer biology, 357
 - 25.5 Enhancing the angiogenic efficacy of mesenchymal stem/stromal cells, 358
 - 25.6 Transdifferentiation of mesenchymal stem/stromal cells towards endothelial cells, 359
 - 25.7 Conclusions, therapeutic expectations, and challenges, 359
 - References, 361
- 26 The relationship between mesenchymal stromal cells and endothelial cells, 366**
Seyed Mahdi Nassiri and Reza Rahbarghazi
 - 26.1 Introduction, 366
 - 26.2 Transendothelial migration of mesenchymal stromal cells, 366
 - 26.2.1 Mesenchymal stromal cell adhesion to endothelial cells, 366
 - 26.2.2 Trans-endothelial migration, 369
 - 26.3 Mesenchymal stromal cell–endothelial cell crosstalk in angiogenesis, 370
 - 26.3.1 Juxtacrine interactions of mesenchymal stromal cells and endothelial cells, 370
 - 26.3.2 Paracrine interactions of mesenchymal stromal cells and endothelial cells, 372
 - 26.4 Mesenchymal stromal cell–endothelial cell crosstalk in tumor angiogenesis, 373
 - 26.4.1 Stimulation, 373
 - 26.4.2 Inhibition, 375
 - 26.5 Endothelial differentiation of mesenchymal stromal cells, 375
 - 26.6 Development of a biologically active niche through bidirectional endothelial cell–stromal cell crosstalk, 378
 - 26.7 Determination of stem cell fate through crosstalk with endothelial cells, 380

- 26.8 Beneficial effects of mesenchymal stromal cell–endothelial cell interactions in some tissue pathologies, 382
- References, 382
- 27 The radioresistance of mesenchymal stromal cells and their potential role in the management of radiation injury, 391**
Tara Sugrue, Irene Calvo-Asensio, and Rhodri Ceredig
 - 27.1 Mesenchymal stromal cells: modulators of hematopoiesis, 391
 - 27.2 The response of mesenchymal stromal cells to ionizing radiation, 393
 - 27.3 The DNA damage response, 394
 - 27.3.1 Sensing damage: DNA damage response initiation, 396
 - 27.3.2 Sending an SOS: DNA damage response signal transduction and amplification, 396
 - 27.3.3 DNA damage checkpoints, 397
 - 27.4 DNA double-strand break repair, 398
 - 27.4.1 Nonhomologous end joining, 398
 - 27.4.2 Homologous recombination, 400
 - 27.4.3 DNA double-strand break repair pathway choice, 400
 - 27.5 Apoptosis, 400
 - 27.6 Cellular senescence, 401
 - 27.7 Stem cells exhibit a mixed response to DNA damage, 401
 - 27.8 The DNA damage response of mesenchymal stromal cells, 401
 - 27.9 Effects of hypoxia on mesenchymal stromal cell radioresistance, 403
 - 27.10 Clinical relevance of mesenchymal stromal cells in radiation injury: two sides to the coin, 405
 - 27.10.1 Mesenchymal stromal cells and hematopoietic stem cell transplantation, 405
 - 27.10.2 Mesenchymal stromal cells and the tumor microenvironment, 406
 - References, 407
- 28 The implications of multipotent mesenchymal stromal cells in tumor biology and therapy, 415**
Pratika Y. Hernanda, Maikel P. Peppelenbosch, and Qiuwei Pan
 - 28.1 Introduction, 415
 - 28.2 Origin and identification of mesenchymal stromal cells in the tumor microenvironment, 415
 - 28.3 The migratory capacity of mesenchymal stromal cells, 416
 - 28.3.1 Intrinsic migratory properties of mesenchymal stromal cells, 416
 - 28.3.2 Stimuli produced by the tumor, 416
 - 28.4 Context-dependent role of mesenchymal stromal cells in the tumor microenvironment, 417
 - 28.4.1 Hypotheses on context-dependent roles of mesenchymal stromal cells in cancer, 417
 - 28.4.2 The tumor-suppressing roles of mesenchymal stromal cells, 418
 - 28.4.3 The tumor-promoting roles of mesenchymal stromal cells, 418
 - 28.5 The potential immunomodulation by mesenchymal stromal cells in the tumor microenvironment, 419
 - 28.5.1 Mesenchymal stromal cells inhibit natural killer cells and macrophages, 419
 - 28.5.2 Mesenchymal stromal cells inhibit T cell proliferation, 420
 - 28.5.3 Mesenchymal stromal cells promote the expansion and function of regulatory T cells, 420
 - 28.5.4 Mesenchymal stromal cells inhibit the function of dendritic cells, 420
 - 28.6 Therapeutic application of mesenchymal stromal cells in cancer, 420
 - 28.6.1 Potential therapeutic application, 420
 - 28.6.2 Reasons for caution, 420
 - Acknowledgments, 421
 - References, 421
- 29 Mesenchymal stem/stromal cell therapy: mechanism of action and host response, 426**
Aideen Ryan, Mary Murphy, and Frank Barry
 - 29.1 Mesenchymal stem/stromal cells, 426
 - 29.2 Therapeutic application of mesenchymal stem/stromal cells, 427
 - 29.3 Mechanism of action, 429
 - 29.4 Host immune response to autologous mesenchymal stem/stromal cell transplantation, 430
 - 29.5 Mesenchymal stromal cells in an inflammatory microenvironment, 430
 - 29.6 Mesenchymal stem/stromal cells-mediated immunomodulation of the innate immune system, 432
 - 29.7 Mesenchymal stem/stromal cells-mediated immune modulation of the adaptive immune system, 434
 - 29.8 Host immune response to transplantation of allogeneic mesenchymal stem/stromal cells, 434
 - 29.9 Summary, 435
 - References, 436
- 30 The differences between mesenchymal stromal cells and fibroblasts, 441**
Luigi Balducci, Sharon Natasha Cox, and Giulio Alessandri
 - 30.1 Introduction, 441
 - 30.2 Phenotypic similarities and differences between mesenchymal stromal cells and fibroblasts, 442
 - 30.3 Cell surface membrane markers, 442

- 30.4 Gene expression profile of mesenchymal stromal cells and fibroblasts, 443
- 30.5 Differentiation potential of mesenchymal stromal cells and fibroblasts, 445
- 30.6 Immune modulation capability of mesenchymal stromal cells and fibroblasts, 446
- 30.7 Modulation of inflammation by mesenchymal stromal cells and fibroblasts, 448
- 30.8 Angiogenic properties of mesenchymal stromal cells and fibroblasts, 450
- 30.9 Conclusions, 451
- References, 451
- 31** Derivation of mesenchymal stem/stromal cells from induced pluripotent stem cells, 456
Rebecca A. Pelekanos
 - 31.1 Introduction, 456
 - 31.2 Mesenchymal stem/stromal cells as candidates for cellular therapy, 457
 - 31.3 Mesenchymal stem/stromal cells, 457
 - 31.4 Adult bone-marrow-derived mesenchymal stem/stromal cells, 457
 - 31.5 Fetal tissue-derived mesenchymal stem/stromal cells, 457
 - 31.6 Embryonic stem cells, 458
 - 31.7 Embryonic stem-cell-derived mesenchymal stem/stromal cells, 458
 - 31.8 Induced pluripotent stem cells, 458
 - 31.9 Small-molecule methods for differentiating pluripotent stem cells into mesenchymal stem/stromal cells, 459
 - 31.10 Derivation of induced pluripotent stem cell–mesenchymal stem/stromal cells through a novel transforming growth factor- β inhibitor method, 459
 - 31.11 Mesenchymal characterization of induced pluripotent stem cell–mesenchymal stem/stromal cells derived through the inhibitor method, 461
 - 31.12 Immune tolerance to induced pluripotent stem cell–mesenchymal stem/stromal cells, 461
 - 31.13 Kinetics of the proliferation of induced pluripotent stem cell–mesenchymal stem/stromal cells, 461
 - 31.14 Tumorigenic potential of induced pluripotent stem cell–mesenchymal stem/stromal cells, 462
 - 31.15 Critical parameters for future preclinical production of induced pluripotent stem cell–mesenchymal stem/stromal cells, 462
 - 31.16 Plasticity of lineage commitment: reprogramming, deprogramming and dedifferentiation, 462
 - 31.17 How to develop “young” mesenchymal stem/stromal cells: going backward to go forward?, 463
 - 31.18 Small-molecules inhibitors for generating “young” stem cells, 463
 - 31.19 Primitive stem cells and mesenchymal stem/stromal cell generation by physical factors, 463
 - 31.20 Conclusions, 463
 - 31.21 Future directions, 464
 - Acknowledgments, 464
 - References, 464
- 32** The role of mesenchymal stem cells in hematopoiesis, 467
Jean-Pierre Levesque, Rebecca N. Jacobsen, and Ingrid G. Winkler
 - 32.1 Introduction, 467
 - 32.2 Hematopoietic stem cells need a niche, 468
 - 32.3 A mesenchymal hierarchy, 468
 - 32.4 Identification of mesenchymal stem cells and their relationship with hematopoietic stem cells in the mouse, 469
 - 32.5 More than one nestin⁺ cell type and hematopoietic stem cell niche exist in the mouse bone marrow, 470
 - 32.6 Controversies surrounding nestin⁺ mesenchymal stem cells and other genetic models for alternative mesenchymal stem cells, 471
 - 32.7 Other stromal cells regulate hematopoietic stem cells and additional tools to study their role in regulating hematopoiesis, 472
 - 32.7.1 Osteoblastic lineage and osteoblasts, 473
 - 32.7.2 Endothelial cells, 473
 - 32.7.3 Megakaryocytes, Schwann cells, and the transforming growth factor- β connection, 474
 - 32.7.4 Adrenergic neurons, 475
 - 32.7.5 Macrophages, 475
 - 32.8 Human mesenchymal stem cells and human hematopoiesis, 476
 - 32.9 Conclusions, 477
 - References, 477
- 33** The modulatory effects of mesenchymal stromal cells on the innate immune system, 481
Ko-Jiunn Liu, Men-Luh Yen, Li-Tzu Wang, and B. Linju Yen
 - 33.1 Introduction to the innate immune system, 481
 - 33.2 Interactions with dendritic cells, 481
 - 33.3 Interactions with monocytes, macrophages, and immature myeloid cells, 483
 - 33.4 Interactions with natural killer lymphocytes, 484
 - 33.5 Interactions with neutrophils, other granulocytes, and mast cells, 485
 - 33.6 Interactions with complement, 485
 - References, 486
- 34** The modulatory effects of mesenchymal stromal cells on the adaptive immune system, 490
B. Linju Yen, Ko-Jiunn Liu, Men-Luh Yen, and Huey-Kang Sytwu

- 34.1 Introduction to the adaptive immune system, 490
- 34.2 Interactions with T lymphocytes, 490
- 34.3 Interactions with B lymphocytes, 492
- References, 492
- 35 The role of mesenchymal stromal cells in the repair of acute organ injury, 496**
A.A. Temnov, A.V. Vagabov, A.N. Sklifas, V.I. Novoselov, and Y.A. Belyi
 - 35.1 Effect of acute organ injury on the proliferative and functional activity of mesenchymal stromal cells, 496
 - 35.1.1 The effect of catecholamines on mesenchymal stromal cells, 496
 - 35.1.2 The impact of hypoxia as a factor of acute injury on mesenchymal stromal cell proliferation, 497
 - 35.1.3 Effect of hypoxia as a factor of acute injury on the paracrine function of mesenchymal stromal cells, 498
 - 35.1.4 Effect of tissue-specific proteins released after acute tissue injury on mesenchymal stromal cells, 501
 - 35.2 Paracrine effect of mesenchymal stromal cells in acute organ injury, 501
 - 35.2.1 Background, 501
 - 35.2.2 Paracrine factors secreted by mesenchymal stromal cells, 502
 - 35.2.3 Immunosuppressive and anti-inflammatory effects of mesenchymal stromal cells, 502
 - 35.2.4 The pro-angiogenic and tissue regenerative effects of mesenchymal stromal cells in acute organ injury, 505
 - 35.2.5 The antiapoptotic activity of mesenchymal stromal cells, 506
 - 35.2.6 Mesenchymal stromal-cell-derived microvesicles: an essential part of the paracrine mechanism, 507
 - 35.3 Mesenchymal-stromal cells in the treatment of acute ischemia–reperfusion injury, 508
 - 35.3.1 Ischemia–reperfusion injury pathogenesis, 509
 - 35.3.2 The use of mesenchymal stromal cells in kidney ischemia–reperfusion injury, 509
 - 35.3.3 Mesenchymal stromal cells and myocardial ischemia–perfusion injury, 510
 - 35.3.4 Mesenchymal stromal cells and ischemia–reperfusion injury of other organs, 511
 - 35.3.5 Conclusions, 511
 - 35.4 The use of mesenchymal stromal cells in acute lung and airway injury, 511
 - 35.4.1 Repair of the proximal regions of the airways after acute injury, 512
 - 35.5 Current approaches to controlled transplantation of mesenchymal stromal cells in acute organ injury, 515
- 35.6 Conclusions, 516
- Acknowledgment, 517
- References, 517
- 36 The use of mesenchymal stromal cells in the treatment of diseases of the cornea, 524**
Damien G. Harkin, Allison J. Sutherland, Laura J. Bray, Leanne Foyn, Fiona J. Li, and Brendan G. Cronin
 - 36.1 Introduction, 524
 - 36.2 Anatomy and physiology of the human cornea, 529
 - 36.3 Overview of corneal pathology, 530
 - 36.3.1 Ocular surface disease, 531
 - 36.3.2 Diseases of the corneal stroma and endothelium, 531
 - 36.4 Corneal transplantation and cultivated epithelial autografts, 532
 - 36.5 Evidence for mesenchymal stromal cells as modulators of corneal disease, 533
 - 36.5.1 Immunology of the cornea, 533
 - 36.5.2 Immunology of corneal transplantation, 534
 - 36.5.3 Immunomodulatory properties of mesenchymal stromal cells, 535
 - 36.5.4 Mesenchymal stromal cells as modulators of corneal wound healing and tissue regeneration, 535
 - 36.5.5 Mesenchymal stromal cells as modulators of corneal transplantation, 536
 - 36.6 Evidence for mesenchymal stromal cells as a source of new corneal cells, 537
 - 36.6.1 Mesenchymal stromal cell differentiation into corneal epithelium, 537
 - 36.6.2 Mesenchymal stromal cell differentiation into keratocytes, 538
 - 36.6.3 Mesenchymal stromal cell differentiation into corneal endothelium, 538
 - 36.7 The biology of cornea-derived mesenchymal stromal cells, 538
 - 36.8 Conclusions and future directions, 540
 - Acknowledgments, 540
 - References, 540
- 37 The role of paracrine factors secreted by mesenchymal stromal cells in acute tissue injury, 544**
Ying Wang, Tania Velletri, Chunxing Zheng, and Yufang Shi
 - 37.1 Introduction, 544
 - 37.2 Cell replacement and cell empowerment, 544
 - 37.3 Paracrine factors produced by mesenchymal stromal cells, 545
 - 37.3.1 Growth factors and mesenchymal-stromal-cell-mediated tissue repair, 546

- 37.3.2 Soluble immunosuppressive factors and mesenchymal-stromal-cell-mediated tissue repair, 546
- 37.3.3 Inducible nitric oxide synthase/indoleamine 2,3-dioxygenase, 547
- 37.3.4 Prostaglandin E₂, 548
- 37.3.5 Tumor-necrosis-factor-inducible gene 6 protein, 548
- 37.3.6 Chemokine (C–C motif) ligand 2, 548
- 37.3.7 Interleukin-6, 548
- 37.3.8 Interleukin-10, 548
- 37.3.9 Transforming growth factor- β , 549
- 37.3.10 Human leukocyte antigen G, 549
- 37.3.11 Galectins, 549
- 37.3.12 Other soluble immunosuppressive factors secreted by MSCs, 549
- 37.4 Conclusions, 549
- Acknowledgments, 549
- References, 549
- 38 Treatment of lung disease by mesenchymal stromal cell extracellular vesicles, 553**
Antoine Monsel, Ying-gang Zhu, Varun Gudapati, and Jae-Woo Lee
 - 38.1 Introduction, 553
 - 38.2 Definitions and characterization of extracellular vesicles, 554
 - 38.3 Nomenclature defined by size and morphology, 555
 - 38.4 Common methods of collection of extracellular vesicles, 556
 - 38.4.1 Ultracentrifugation, 556
 - 38.4.2 Size exclusion, 556
 - 38.4.3 Immunoaffinity isolation, 556
 - 38.4.4 Polymeric precipitation, 556
 - 38.5 Quantification of extracellular vesicles, 556
 - 38.5.1 Optical single-particle tracking: nanoparticle tracking analyses, 556
 - 38.5.2 Flow cytometry, 557
 - 38.5.3 Electron microscopy, 557
 - 38.5.4 Protein concentration, 557
 - 38.5.5 Cell count, 557
 - 38.6 Interaction of extracellular vesicles with targeted cells, 557
 - 38.7 Endogenous extracellular vesicles in lung disease, 558
 - 38.7.1 Endogenous extracellular vesicles in acute respiratory distress syndrome, 558
 - 38.7.2 Endogenous extracellular vesicles in chronic obstructive pulmonary disease, 560
 - 38.7.3 Endogenous extracellular vesicles in asthma, 561
 - 38.7.4 Endogenous extracellular vesicles as biomarkers in lung disease, 561
 - 38.7.5 Endogenous extracellular vesicles as potential therapeutic targets for lung diseases, 562
 - 38.8 Therapeutic properties of extracellular vesicles derived from mesenchymal stromal cells, 562
 - 38.8.1 Mesenchymal stromal cell vesicles for kidney injury, 562
 - 38.8.2 Mesenchymal stromal cell vesicles for cardiac injury, 564
 - 38.8.3 Mesenchymal stromal cell vesicles for liver injury, 565
 - 38.8.4 Mesenchymal stromal cell vesicles for neural injury, 565
 - 38.8.5 Mesenchymal stromal cell vesicles for lung diseases, 565
 - 38.9 Remaining questions on the therapeutic use of mesenchymal stromal cell extracellular vesicles, 566
 - 38.9.1 Isolation and quantification techniques, 566
 - 38.9.2 Extracellular vesicle characterization, 566
 - 38.9.3 Feasibility of large-scale generation of extracellular vesicles, 566
 - 38.10 Regulatory considerations for the clinical use of extracellular vesicles, 566
 - 38.11 Conclusions, 566
 - References, 567
- 39 Evaluating mesenchymal stem/stromal cells for treatment of asthma and allergic rhinitis, 573**
Tatyana Gavrilova, Saritha Kartan, Lauren S. Sherman, Oleta A. Sandiford, and Pranela Rameshwar
 - 39.1 Summary, 573
 - 39.2 Introduction, 573
 - 39.3 Early and late asthma response, 573
 - 39.4 Airway remodeling, 574
 - 39.5 Innate immunity of the airway, 574
 - 39.6 Adaptive immunity of the respiratory tract, 575
 - 39.7 Toll-like receptors, 575
 - 39.8 Allergic rhinitis and immunology, 575
 - 39.9 Immune modulation by mesenchymal stem/stromal cells, 577
 - 39.10 The future of mesenchymal stem/stromal cells as therapy for allergic diseases, 578
 - References, 578
- 40 Stem cell therapies for Huntington's disease, 581**
A.T. Crane, J. Rossignol, and G. L. Dunbar
 - 40.1 Introduction, 581
 - 40.2 Huntington's disease, 581
 - 40.2.1 Prevalence and symptomology, 582
 - 40.2.2 Neuronal pathology, 582
 - 40.2.3 Mechanisms of neurodegeneration, 583
 - 40.3 Animal models, 584
 - 40.3.1 Transgenic models, 584
 - 40.4 *In vitro* models, 584

- 40.5 Experimental therapies, 585
- 40.6 Cell transplantation, 585
 - 40.6.1 Mesenchymal stem/stromal cells, 585
 - 40.6.2 Genetic engineering of mesenchymal stem/stromal cells, 587
 - 40.6.3 Embryonic and fetal stem cells, 588
 - 40.6.4 Neural stem cells, 589
 - 40.6.5 Induced pluripotent stem cells, 590
 - 40.6.6 Co-transplantation paradigm, 593
- 40.7 Conclusions, 593
- References, 594

Section IV: The role of bioengineering in the therapeutic applications of mesenchymal stromal cells

- 41** Endometrial mesenchymal stromal cell and tissue engineering for pelvic organ prolapse repair, 601
Shanti Gurung, Jerome A. Werkmeister, and Caroline E. Gargett
 - 41.1 Introduction, 601
 - 41.2 Pelvic floor disorders, 601
 - 41.3 Pelvic organ prolapse, 602
 - 41.3.1 Surgical treatment for pelvic organ prolapse, 602
 - 41.3.2 New meshes for treatment of pelvic organ prolapse, 603
 - 41.4 Tissue engineering, 603
 - 41.4.1 Candidate cells for tissue engineering applications for pelvic organ disorders, 603
 - 41.5 Endometrium is highly regenerative and contains stem/stromal cells, 606
 - 41.5.1 Human endometrial mesenchymal stem/stromal cells, 606
 - 41.6 Culture expansion of endometrial mesenchymal stem/stromal cells toward current good manufacturing practice conditions, 608
 - 41.7 Tissue engineering for pelvic organ prolapse repair, 609
 - 41.7.1 A large animal preclinical model for pelvic organ prolapse, 611
 - 41.8 Conclusions, 612
- Acknowledgments, 612
- References, 612
- 42** Closed automated large-scale bioreactors for manufacturing mesenchymal stromal cells for clinical use, 616
Kerry Atkinson, Nicholas Timmins, G. Kiel, Celena Heazlewood, Michael Doran, and Gary Brooke
 - 42.1 Introduction, 616
 - 42.2 Design of a semi-automated closed-system bioreactor capable of manufacturing mesenchymal stromal cells for clinical use, 616

- 42.3 A commercially available closed-system bioreactor for manufacturing mesenchymal stromal cells for clinical use, 617
- References, 618

Section V: GMP manufacturing of mesenchymal stromal cells for clinical use

- 43** Current good manufacturing practice for the isolation and *ex vivo* expansion of mesenchymal stromal cells derived from term human placenta for use in clinical trials, 621
Kerry Atkinson, Dahlia Khalil, Celena Heazlewood, and Nina Ilic
 - 43.1 Source of mesenchymal stromal cells for use in clinical trials, 621
 - 43.2 Inclusion criteria for mothers wishing to donate their term placenta for isolation and expansion of mesenchymal stromal cells for use in clinical trials approved by a human research ethics committee, 622
 - 43.3 Exclusion criteria for mothers wishing to donate their term placenta for isolation and expansion of mesenchymal stromal cells for use in clinical trials approved by a human research ethics committee, 622
 - 43.4 Mesenchymal stromal cell manufacturing, 623
 - 43.4.1 The good manufacturing process facility, 623
 - 43.4.2 Quality control and quality assurance, 623
 - 43.4.3 Isolating and expanding mesenchymal stromal cells from human term placenta, 623
 - 43.4.4 Testing performed on mesenchymal stromal cells manufactured for clinical use, 623
 - 43.5 Phase 1 trials using placenta-derived mesenchymal stromal cells, 625
- References, 627
- 44** A comparison of high-tier regulatory documents pertaining to biologic drugs including mesenchymal stromal cells in Australia, Europe, and the USA using a manual documentary analysis, 628
Nina Ilic
 - 44.1 Introduction, 628
 - 44.2 Background, 628
 - 44.3 Definitions used by the Australian Therapeutic Goods Administration, the European Medicine Agency, and the US Food and Drug Administration for “biologicals”, 629
 - 44.4 Complexity of the area, 632
 - 44.5 Analysis of documents, 633

- 44.6 Regulatory science, 639
- 44.7 Interpretation of the analysis of the documents, 640
- 44.8 Conclusions, 641
- References, 641

Section VI: The therapeutic application of mesenchymal stromal cells

45 The use of mesenchymal stromal cells in acute and chronic heart disease, 647

Ariel Wolf, Wayne Balkan, and Joshua Hare

- 45.1 Introduction, 647
- 45.2 The biology of acute and chronic ischemic cardiomyopathy, 647
- 45.3 Characterization of mesenchymal stromal/stem cells, 648
 - 45.3.1 Immunomodulatory properties, 649
 - 45.3.2 Antifibrotic effects, 650
 - 45.3.3 Cardiomyogenesis *in vitro* and *in vivo*, 650
 - 45.3.4 Neovascularization, 651
 - 45.3.5 Paracrine effects, 652
 - 45.3.6 Exosomes, 652
 - 45.3.7 Mitochondrial transfer, 652
 - 45.3.8 Preconditioning, 652
 - 45.3.9 Genetic modification, 653
- 45.4 Cell combination therapy, 653
- 45.5 Clinical trials utilizing bone-marrow-derived mesenchymal stromal/stem cells, 654
 - 45.5.1 Acute myocardial infarction, 654
 - 45.5.2 Chronic myocardial infarction, 655
- 45.6 Clinical trials utilizing adipose-derived mesenchymal stromal/stem cells, 656
- 45.7 Preconditioning in the clinical setting, 657
- 45.8 Conclusions, 657
- References, 657

46 The role of mesenchymal stem/stromal cells in the management of critical limb ischemia, 661

P.K. Gupta, Chullikana Anoop, Balasubramanian Sudha, R Mathiazhagan, Raj Swathi Sundar, and Majumdar Anish Sen

- 46.1 Introduction, 661
- 46.2 Mesenchymal stem/stromal cells and angiogenesis, 663
- 46.3 Potency assays for cells to be used in critical limb ischemia, 664
 - 46.3.1 Ixmyelocel-T, 664
 - 46.3.2 Stempeucel®, 665
- 46.4 Preclinical studies, 665
 - 46.4.1 Preclinical safety studies, 665
 - 46.4.2 Preclinical efficacy studies, 667
- 46.5 Clinical trials in critical limb ischemia, 667

- 46.5.1 Safety of mesenchymal stromal cells in clinical trials, 667
- 46.5.2 Efficacy of mesenchymal stromal cells in clinical trials of critical limb ischemia, 668
- 46.5.3 Clinical trials in India, 671
- 46.5.4 Stempeutics research experience in critical limb ischemia, 671
- 46.5.5 Phase I/II study in patients with critical limb ischemia, 671
- 46.5.6 Phase II study in patients with Buerger's disease, 673

46.6 Conclusions, 673
References, 674

47 The role of mesenchymal stromal cells in the management of musculoskeletal disorders, 677

Stefan Zwingenberger, Ishaq Ojodu, Maik Stiehler, and Stuart B. Goodman

- 47.1 Summary, 677
- 47.2 Introduction, 677
- 47.3 Stem cells for bone regeneration, 679
 - 47.3.1 Bone defects, 679
 - 47.3.2 Osteonecrosis, 680
 - 47.3.3 Wear-particle-related osteolysis, 681
 - 47.3.4 Systemic bone diseases, 681
- 47.4 Stem cells for cartilage regeneration, 682
 - 47.4.1 Osteoarthritis, 683
- 47.5 Stem cells for tendon regeneration, 683
- 47.6 Stem cells for skeletal muscle regeneration, 684
- 47.7 Stem cells for wound repair, 685
- 47.8 Conclusions, 685
- References, 685

48 The potential role of bone marrow mesenchymal stromal cells in the treatment of ischemic stroke, 690

Yujun Pan and Ruohan Sun

- 48.1 Introduction, 690
 - 48.1.1 Stroke, 690
 - 48.1.2 Stem cells, 691
 - 48.1.3 Mesenchymal stromal cells, 691
- 48.2 Transplantation route and mechanisms of migration, 693
- 48.3 Tracking techniques for transplanted mesenchymal stromal cells, 698
- 48.4 Cytokines and neurotrophic factors, 699
- 48.5 Angiogenesis, 699
- 48.6 Neurogenesis, 700
- 48.7 Axonal sprouting and remyelination, 701
- 48.8 Antiapoptotic effects, 701
- 48.9 Immunomodulation, 702
- 48.10 Pretreatment of mesenchymal stromal cells prior to their administration in animal models of ischemic stroke, 702

- 48.10.1 Administration of genetically engineered mesenchymal stromal cells, 704
- 48.10.2 Administration of mesenchymal stromal cells in combination with chemical agents, 704
- 48.11 Clinical trials involving bone-marrow-derived mesenchymal stromal cells in the treatment of ischemic stroke, 705
- 48.12 Controversies and safety analysis of bone-marrow-derived mesenchymal stromal cells in the treatment of ischemic stroke, 706
 - 48.12.1 Conflicting results in animal models, 706
 - 48.12.2 Combined transplantation of mesenchymal stromal cells and neural stem/precursor cells, 706
- 48.13 Conclusions and perspectives, 707
- Acknowledgments, 707
- References, 707
- 49 The role of mesenchymal stromal cells in spinal cord injury, 714**
P. Jendelova, L. Machova-Urdzikova, and E. Sykova
 - 49.1 The central nervous system, 714
 - 49.2 Spinal cord injury, 714
 - 49.3 Cell therapy, 715
 - 49.3.1 Mesenchymal stromal cells, 716
 - 49.4 Chronic spinal cord injury, 721
 - 49.5 Cellular transplants for spinal cord injury, 722
 - 49.5.1 Use of hematopoietic stem/progenitor cells for spinal cord injury, 722
 - 49.5.2 Use of mesenchymal stromal cells for spinal cord injury, 723
 - 49.6 Conclusions, 723
 - Acknowledgments, 725
 - References, 725
- 50 The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn's disease, 730**
Céline Gregoire, Chantal Lechanteur, Alexandra Briquet, Etienne Baudoux, Olivier Giet, Olivier Delloye, Frédéric Baron, Edouard Louis, and Yves Beguin
 - 50.1 Inflammatory bowel diseases, 730
 - 50.2 Pathogenesis of inflammatory bowel diseases, 731
 - 50.3 Treatment of Crohn's disease, 734
 - 50.3.1 Current treatment options for Crohn's disease, 734
 - 50.3.2 Potential treatment options, 735
 - 50.4 Treatment of ulcerative colitis, 737
 - 50.4.1 Current treatment options for ulcerative colitis, 737
 - 50.4.2 Potential new treatment options, 737
 - 50.5 Properties of mesenchymal stromal cells, 737
 - 50.5.1 Immunomodulation, 738
 - 50.5.2 Immune tolerance, 739
 - 50.5.3 Tissue regeneration, 740
 - 50.5.4 Homing, 740
 - 50.5.5 Differentiation and stimulation of tissue repair, 740
 - 50.6 Mesenchymal stromal cell administration in inflammatory bowel diseases, 740
 - 50.6.1 Mesenchymal stromal cell administration for fistulizing Crohn's disease, 741
 - 50.6.2 Autologous mesenchymal stromal cell administration for fistulizing Crohn's disease, 741
 - 50.6.3 Allogeneic mesenchymal stromal cell administration for fistulizing Crohn's disease, 742
 - 50.6.4 Autologous mesenchymal stromal cell administration for luminal inflammatory bowel diseases, 742
 - 50.6.5 Allogeneic mesenchymal stromal cell administration for luminal inflammatory bowel diseases, 742
 - 50.7 The future of mesenchymal stromal cell treatment in inflammatory bowel diseases, 743
 - 50.7.1 Ongoing protocols, 743
 - 50.8 Issues to be resolved, 744
 - 50.8.1 Source of mesenchymal stromal cells, 744
 - 50.8.2 Autologous versus allogeneic mesenchymal stromal cells, 745
 - 50.8.3 Dosage and modalities of administration, 745
 - 50.8.4 Concomitant use of other drugs, 745
 - 50.9 Safety, 745
 - 50.10 Conclusions, 745
 - References, 746
- 51 Mesenchymal stromal cells targeting kidney disease: benefits of a combined therapeutic approach, 754**
Brooke M. Huuskes and Sharon D. Ricardo
 - 51.1 Introduction, 754
 - 51.2 Immune modulation and protective effects of mesenchymal stromal cells, 754
 - 51.3 Mesenchymal stromal cell homing, recruitment, and tracking, 757
 - 51.4 Mechanisms of kidney injury and capacity for repair, 759
 - 51.5 Kidney injury and repair in balance with fibrosis, 759
 - 51.6 Mesenchymal stromal cells as delivery tools for therapies, 760
 - 51.7 Clinical trials with mesenchymal stromal cells, 761
 - 51.8 The antifibrotic functions of relaxin, 763
 - 51.9 Combination therapy using mesenchymal stromal cells and relaxin, 764
 - 51.10 Conclusions, 764
 - References, 765

- 52** The biology and potential clinical applications of mesenchymal stromal cells in diseases of the lung, 770
Yuben P. Moodley, Jesse D. Armitage, and Dino B.A. Tan
- 52.1 Introduction to lung disease, 770
 - 52.1.1 The global burden of lung disease, 770
 - 52.1.2 The pathogenesis of lung diseases, 770
 - 52.1.3 The range of lung diseases, 771
 - 52.2 What are stem cells?, 771
 - 52.3 What are mesenchymal stromal cells?, 771
 - 52.4 Lung-resident mesenchymal stromal cells, 772
 - 52.5 Tracking mesenchymal stromal cells in the body, 772
 - 52.6 The properties of mesenchymal stromal cells that favor repair, 772
 - 52.6.1 Avoidance of immune recognition, 772
 - 52.6.2 Mechanisms of mesenchymal stromal-cell-mediated immunomodulation, 772
 - 52.6.3 Mesenchymal stromal-cell-mediated repair via trophic factors, 775
 - 52.7 Mesenchymal stromal cells as delivery agents for drugs, 775
 - 52.7.1 Viral transduction, 775
 - 52.7.2 Genetic modulation, 776
 - 52.7.3 Nanoparticle incorporation, 776
 - 52.7.4 Surface modification, 776
 - 52.7.5 Preconditioned mesenchymal stromal cells, 776
 - 52.8 Preclinical and clinical studies of mesenchymal stromal cells in pulmonary diseases, 776
 - 52.8.1 Idiopathic pulmonary fibrosis, 776
 - 52.8.2 Chronic obstructive pulmonary disease, 779
 - 52.8.3 Acute lung injury and acute respiratory distress syndrome, 780
 - 52.9 Challenges in mesenchymal stromal cell administration in lung diseases, 781
 - 52.9.1 Optimal dosage of mesenchymal stromal cells, 781
 - 52.9.2 Timing of mesenchymal stromal cell administration, 782
 - 52.10 Summary and conclusions, 782
 - References, 782
- 53** The role of mesenchymal stromal cells in diseases of the lung, 787
Kerry Atkinson
- 53.1 Introduction, 787
 - 53.2 Pulmonary fibrosis, 787
 - 53.2.1 Animal models, 788
 - 53.2.2 Clinical trials of mesenchymal stromal cells, 788
 - 53.3 Asthma, 788
 - 53.3.1 Preclinical models, 790
 - 53.3.2 Clinical trials of mesenchymal stromal cells, 790
 - 53.4 Obliterative bronchiolitis, 790
 - 53.4.1 Preclinical animal models, 790
 - 53.4.2 Clinical trials of mesenchymal stromal cells, 791
 - 53.5 Chronic obstructive pulmonary disease and emphysema, 791
 - 53.5.1 Preclinical animal models, 792
 - 53.5.2 Clinical trials with mesenchymal stromal cells, 792
 - 53.6 Bronchopulmonary dysplasia, 792
 - 53.6.1 Preclinical animal models, 792
 - 53.6.2 Clinical trials using mesenchymal stromal cells, 792
 - 53.7 Acute respiratory distress syndrome and acute lung injury, 792
 - 53.7.1 Preclinical animal models, 793
 - 53.7.2 Clinical trials with mesenchymal stromal cells, 793
 - 53.8 Conclusions, 793
 - References, 793
- 54** Mesenchymal stromal cells for the treatment of autoimmune diseases, 794
Christopher N. Lewis and Jacques Galipeau
- 54.1 Cell biology of endogenous mesenchymal stromal cells, 794
 - 54.1.1 Mesenchymal stromal cells coordinate hematopoietic stem cell development, 795
 - 54.1.2 Mesenchymal stromal cells and central tolerance in the bone marrow, 795
 - 54.2 Cell biology of mesenchymal stromal cells in culture, 796
 - 54.2.1 Mesenchymal stromal cells and B cell immunosuppression, 797
 - 54.2.2 Mesenchymal stromal cell and T cell co-culture assays, 797
 - 54.3 Immunosuppression: lessons from oncology, 797
 - 54.3.1 Programmed death ligand 1 and immunosuppression by tumors, 798
 - 54.3.2 Programmed death ligand 1 and immunosuppression by mesenchymal stromal cells, 798
 - 54.3.3 Indoleamine 2,3-dioxygenase and immunosuppression by tumors, 799
 - 54.3.4 Indoleamine 2,3-dioxygenase and immunosuppression by mesenchymal stromal cells, 799
 - 54.4 Mesenchymal stromal cell response to inflammatory signals: licensing and integration, 800
 - 54.4.1 Mesenchymal stromal cells and complement, 800
 - 54.4.2 Mesenchymal stromal cells and toll-like receptors, 801
 - 54.4.3 Interferon- γ in the immune response, 802

- 54.4.4 Mesenchymal stromal cells and interferon- γ , 803
- 54.4.5 Tumor necrosis factor- α in the immune response, 803
- 54.4.6 Synergy of interferon- γ and tumor necrosis factor- α in mesenchymal stromal cells, 804
- 54.5 Strength of signal and integration, 804
- 54.6 Clinical applications of mesenchymal stromal cells for immune-mediated diseases, 806
 - 54.6.1 How *in vitro* data inform assessment of clinical efficacy, 806
 - 54.6.2 Random donor, industrial scale, 806
 - 54.6.3 Allogeneic mesenchymal stromal cells, low passage, 807
 - 54.6.4 Autologous mesenchymal stromal cells for autoimmune diseases, 808
- 54.7 Conclusions and next steps, 809
- References, 809
- 55** The role of mesenchymal stromal cells in bacterial infection, 814
Sailaja Ghanta, Konstantin Tsoyi, and Mark A. Perrella
 - 55.1 Introduction, 814
 - 55.2 Experimental models of bacterial infection and sepsis, 815
 - 55.3 Effects of mesenchymal stromal cells on the innate immune response, 816
 - 55.4 Effects of mesenchymal stromal cells on the adaptive immune response, 819
 - 55.5 Antimicrobial activity of mesenchymal stromal cells, 819
 - 55.6 Mesenchymal stromal cells and endothelial/epithelial dysfunction, 819
 - 55.7 Mesenchymal stromal cells and effect on organ injury in infection, 819
 - 55.8 Mesenchymal stromal cell cytokine and growth factor production, 820
 - 55.9 Toll-like receptors and mesenchymal stromal cells, 821
 - 55.10 Mesenchymal stromal cell homing, 821
 - 55.11 Mesenchymal stromal cell response to oxidative stress, 821
 - 55.12 Paracrine effects of mesenchymal stromal cells, 821
 - 55.13 Transcriptomic analysis of mesenchymal stromal cell therapy in sepsis, 822
 - 55.14 Summary, 822
 - References, 822
- 56** The use of mesenchymal stromal cells in solid organ transplantation, 825
Céline Gregoire, Alexandra Briquet, François Jouret, Chantal Lechanteur, Etienne Baudoux, Olivier Giet, Olivier Delloye, Frédéric Baron, Olivier Detry, and Yves Beguin
 - 56.1 Introduction, 825
 - 56.2 Potential effects of mesenchymal stromal cells in solid organ transplantation, 825
 - 56.3 Immunomodulation, 826
 - 56.4 Tissue and organ regeneration, 826
 - 56.5 Prevention of ischemia–reperfusion injury, 826
 - 56.6 Mesenchymal stromal cell administration in solid organ transplantation, 826
 - 56.6.1 Kidney transplantation, 826
 - 56.6.2 Liver transplantation, 829
 - 56.6.3 Heart transplantation, 831
 - 56.6.4 Lung transplantation, 831
 - 56.6.5 Pancreas and islet transplantation, 831
 - 56.6.6 Bowel transplantation, 832
 - 56.7 Conclusions, 832
 - References, 832
- 57** The role of mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation, 836
Kerry Atkinson
 - 57.1 The immunobiology of allogeneic hematopoietic stem cell transplantation, 836
 - 57.1.1 Graft rejection and late marrow failure, 836
 - 57.1.2 Graft-versus-host disease, 836
 - 57.1.3 The graft-versus-leukemia effect, 837
 - 57.1.4 The recipient's response to infection, 837
 - 57.2 The immunobiology of mesenchymal stromal cells, 837
 - 57.3 The role of mesenchymal stromal cells in the expansion of hematopoietic stem cells, 837
 - 57.4 The role of mesenchymal stromal cells in marrow graft rejection, 837
 - 57.5 The role of mesenchymal stromal cells in the prevention of acute graft-versus-host disease, 838
 - 57.6 The role of mesenchymal cells in the treatment of corticosteroid-refractory acute graft-versus-host disease, 838
 - 57.7 The mesenchymal stromal cell exosome: a substitute for the mesenchymal stromal cell?, 839
 - References, 839
- 58** The role of mesenchymal stromal cells in the management of skin wounds, 841
Sung-Whan Kim
 - 58.1 Introduction, 841
 - 58.2 The wound healing process, 841
 - 58.3 The role of mesenchymal stromal cells in the wound healing process, 842
 - 58.3.1 Immune modulation, 842
 - 58.3.2 Antimicrobial activity, 842
 - 58.3.3 Chemotactic and migratory activities, 842
 - 58.3.4 Paracrine activity, 842
 - 58.3.5 Differentiation, 842
 - 58.4 Conclusions and the future, 842
 - References, 843

59 The role of mesenchymal stromal cells in skin wound healing, 845

Miao Teng and Hengshu Zhang

- 59.1 Summary, 845
- 59.2 Introduction, 845
- 59.3 The role of bone-marrow-derived mesenchymal stromal cells in wound healing, 845
- 59.4 The role of adipose-tissue-derived mesenchymal stromal cells in wound healing, 849
- 59.5 The role of mesenchymal stromal cells from placental tissues in wound healing, 851
- 59.6 The role of mesenchymal stromal cells from dermal tissue in wound healing, 852
- 59.7 The role of mesenchymal stromal cells from blood in wound healing, 853
- 59.8 Questions and challenges regarding mesenchymal stromal cell administration in wound healing, 853
- 59.9 Conclusions, 853
- References, 853

Section VII: Mesenchymal stromal cells as delivery vehicles for therapeutic agents

60 The role of mesenchymal stromal cells in human brain tumors, 859

Brittany C. Parker Kerrigan, Tal Shahar, Shinji Yamashita, and Frederick F. Lang

- 60.1 Introduction, 859
- 60.2 Mesenchymal stromal cells in the therapy of human gliomas, 860
- 60.3 Cellular therapy for gliomas, 860
- 60.4 The advantages of mesenchymal stromal cells in clinical use, 861
- 60.5 The rationale for using mesenchymal stromal cells in glioma therapy, 861
- 60.6 Mechanisms underlying mesenchymal stromal cell tropism for gliomas, 863
- 60.7 Strategies to enhance mesenchymal stromal cell homing to gliomas, 864
- 60.8 Types of therapeutic cargo, 864
 - 60.8.1 Secreted proteins, 864
 - 60.8.2 Prodrug enzymes, 865
 - 60.8.3 Replication-competent oncolytic viruses, 865
 - 60.8.4 Antibodies, 866
 - 60.8.5 Nanoparticles, 866
- 60.9 Delivery routes of mesenchymal stromal cells in clinical applications, 866
- 60.10 Mesenchymal stem cells in the biology of gliomas, 867

60.11 Controversy over tumor-associated mesenchymal stromal cells in solid tumors and gliomas, 867

60.12 A model of mesenchymal stromal cells in glioma biology, 868

60.13 Prospects for clinical use of bone-marrow-derived mesenchymal stromal cells in glioma therapy, 868

References, 869

61 Mesenchymal stromal cells as gene delivery vehicles to treat nonmalignant diseases, 873

Julie R. Beegle, Jan A. Nolte, and Fernando A. Fierro

- 61.1 Introduction, 873
- 61.2 What are mesenchymal stromal cells?, 873
- 61.3 Genetic modification of mesenchymal stromal cells, 874
 - 61.3.1 Safety concerns, 874
 - 61.3.2 Choice of vector system, 874
- 61.4 Preclinical models of gene-modified mesenchymal stromal cells: mesenchymal stromal cell migration and survival, 875
- 61.5 Gene-modified mesenchymal stromal cells as immune modulators, 877
- 61.6 Gene-modified mesenchymal stromal cells in skeletal disorders, 878
- 61.7 Gene-modified mesenchymal stromal cells in cardiovascular disease, 880
- 61.8 Gene-modified mesenchymal stromal cells in kidney disease, 881
- 61.9 Gene-modified mesenchymal stromal cells in neurological disease, 881
- 61.10 Gene-modified mesenchymal stromal cells in other nonmalignant diseases, 883
 - 61.10.1 Hemophilia, 883
 - 61.10.2 Metachromatic leukodystrophy, 883
 - 61.10.3 Mucopolysaccharidosis type VII, 883
 - 61.10.4 Diabetes mellitus, 883
- 61.11 Conclusions and future directions, 883
- References, 885

62 Gene therapy for cancer using mesenchymal stromal cells, 892

Ryosuke Uchibori and Keiya Ozawa

- 62.1 Introduction, 892
 - 62.1.1 Biological characteristics of mesenchymal stromal cells, 892
 - 62.1.2 Immunomodulatory effects of mesenchymal stromal cells on immune cells, 893
 - 62.1.3 Tumor homing of mesenchymal stromal cells, 893
- 62.2 Applications of genetically engineered mesenchymal stromal cells for cancer therapy, 893
 - 62.2.1 Interferons, 893
 - 62.2.2 Interleukins, 894

- 62.2.3 Chemokines, 894
- 62.2.4 Suicide genes, 894
- 62.2.5 Other approaches, 894
- 62.3 Molecular mechanisms of mesenchymal stromal cell accumulation at tumor sites, 894
 - 62.3.1 Migratory factors, 895
 - 62.3.2 Interactions between mesenchymal stromal cells and endothelial cells, 895
- 62.4 Considerations in the use of genetically engineered mesenchymal stromal cells in cancer therapy, 895
- 62.5 Summary and conclusions, 896
- References, 896

Section VIII: The present and the future

- 63** Breaking news, 901
Kerry Atkinson
 - 63.1 *In vitro* laboratory studies, 901
 - 63.2 Preclinical *in vivo* animal studies, 903
 - 63.3 Clinical trials, 908
 - 63.4 Regulatory approval for marketing mesenchymal stromal cell products, 909
- References, 909

- 64** Reconciling the stem cell and paracrine paradigms of mesenchymal stem cell function, 912
Siddaraju V. Boregowda and Donald G. Phinney
 - 64.1 Summary, 912
 - 64.2 Introduction, 912
 - 64.3 The stem cell paradigm revisited, 913
 - 64.4 The paracrine paradigm, 914
 - 64.4.1 “Mesenchymal stem cell pharmacology”: cells are not drug-like, 915
 - 64.4.2 Priming to enhance mesenchymal stem cell paracrine action also impacts cell growth and survival, 916
 - 64.4.3 Licensing of immunomodulatory activity biases cell differentiation, 916
 - 64.5 Modeling mesenchymal stem cell function using lessons learned from immunology, 916
 - 64.6 A stem-cell-centric view of mesenchymal stem cells, 919
 - 64.7 Closing remarks, 920
- References, 920

Glossary, 927

Index, 949